Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Filings indexed 427 across all filing types
Latest filing 2022-03-25 Board/Management Inform…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative directors (CEO). It explicitly lists the 'before' and 'after' status of the representative directors, the reason for the change, and the date of the board resolution. This aligns perfectly with the definition for Board/Management Information (MANG).
2022-03-25 Korean
유상증자결정(종속회사의주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Genome & Company) regarding a decision to increase capital (paid-in capital increase) for its subsidiary, List Biotherapeutics, Inc. It details the number of shares, purpose of funds, and the third-party allocation details. This falls under the category of capital and financing updates.
2022-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by the company. It contains key financial data, audit opinions, and financial statements for the fiscal year. While it provides financial summaries, it is a regulatory filing specifically announcing the submission of the audit report to the exchange (KRX), which is a standard regulatory requirement in South Korea. Given the structure and the nature of the filing as a formal notification of the audit report's availability and key findings, it falls under the category of Regulatory Filings. FY 2021
2022-03-21 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for Genome & Company for the fiscal year ending December 31, 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a formal, full-year financial audit document, which falls under the 'Audit Report / Information' category. FY 2021
2022-03-21 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Genome & Company. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is sent to shareholders to provide information and request votes for an upcoming meeting, which aligns with the definition of a Proxy Solicitation & Information Statement.
2022-03-14 Korean
주주총회소집공고
AGM Information Classification · 99% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Genome & Company. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities, board activities, and financial statements. This document is a standard proxy statement/notice package provided to shareholders to inform them of the upcoming AGM and solicit their votes, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.